Clinical Trial Update: A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial to evaluate ovarian suppression using ZOLADEX 10.8 mg in premenopausal women with HR-positive, HER2-negative advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Zoladex (goserelin)

Snippet

Sponsor: TerSera Therapeutics LLC | Conditions: Advanced Breast Cancer | Phase 1 | Status: NOT_YET_RECRUITING